Evonik Rebuffs BASF's $12.5B Sweetened Bid — But Keeps a Door Ajar

Event Analysis

Evonik Industries' executive board formally rejected BASF's latest takeover approach on October 30, 2026, just eight days after receiving BASF's October 22 letter. As reported by Reuters and confirmed via Evonik's own ad-hoc statement, BASF's improved proposal valued Evonik at approximately €11.18 billion (~$12.5 billion), or €24 per share — a step up from the earlier €22.15 per share offer that was turned away in September. Crucially, Evonik stopped short of closing every door: the board offered to engage in "purely informational and confidential" exchanges with BASF, preserving optionality without entering formal deal negotiations.

This is the second rejected approach in roughly six weeks, which signals a clear valuation gap and strategic disagreement rather than a simple procedural brush-off. The involvement of RAG-Stiftung — Evonik's largest shareholder — makes the situation more complex: BASF separately confirmed that exploratory discussions involving RAG-Stiftung remain open, per BASF's own investor communications. A combined BASF-Evonik entity would have formed one of Europe's largest chemicals platforms, with meaningful overlap in specialty materials, performance chemicals, and industrial inputs. That strategic logic hasn't evaporated with this rejection.

The broader backdrop matters here. European chemical producers face sustained competitive pressure from lower-cost Asian and Middle Eastern rivals, giving consolidation a structural rationale beyond near-term deal economics. This episode fits squarely within the global acquisition and consolidation wave reshaping capital-intensive industries. For Evonik specifically, the rejection reframes it as a company betting on standalone value — a higher-conviction stance given that two sweetened bids have now been turned away.

For the M&A landscape, the "informational talks" carve-out is telling. It keeps a negotiated path alive while blocking a formal process, suggesting Evonik's board may be probing for a higher number rather than a permanent rejection. Traders familiar with acquisition repricing mechanics will recognise this as a classic negotiating posture — not capitulation, not closure.

What This Means for Traders

The immediate market read is moderately negative for Evonik relative to a deal-premium scenario: Evonik-related securities fell roughly 1.2% in European trading post-rejection, per TradingView/SeekingAlpha, as investors trimmed takeover-premium expectations. The stock now reverts toward standalone chemical-cycle valuation — sensitive to restructuring progress, earnings delivery, and feedstock costs rather than bid arithmetic. For BASF, avoiding a potentially overpriced acquisition could be read as balance-sheet discipline, though sentiment will track whether the company escalates, walks away, or attempts a direct shareholder approach.

The key catalysts to watch are: a formal public offer launch by BASF (which has not occurred), RAG-Stiftung declaring a firm position, BASF raising its price above €24, or a definitive abandonment announcement. Until one of these materialises, Evonik is likely to trade as an independent specialty chemicals name — not at full deal premium. Traders playing acquisition arbitrage should note the spread reflects meaningful deal uncertainty, not near-term closing probability.

At the sector level, the episode reinforces consolidation premium awareness across European specialty chemicals. Peers with similar profiles — exposed to automotive, construction, and performance materials — may see modest re-rating as investors consider who the next consolidation target could be. Cross-market effects on natural gas (a key feedstock cost driver for European chemicals) and the DAX Index are indirect and unlikely to produce a standalone trading signal from this event alone.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices and commodities from one crypto-funded account. Leverage up to 2000x on selected products, subject to eligibility; fees are tiered by 30-day volume.